Regulators Now Expect Submission-Ready Data From Phase I

AXIS Clinicals USA is warning drug sponsors that the days of treating Phase I trials as purely exploratory are over, urging companies to build their global regulatory strategy from the very first stage of clinical development rather than waiting until later phases.

The era of treating first-in-human trials as a purely exploratory checkpoint is ending. According to the company’s blog, the expectation that early-phase clinical trials are purely exploratory is quickly becoming outdated, as regulators worldwide push companies to think about global submissions from the very start of clinical development. 

A New Starting Line for Regulatory Strategy

The post argues that health authorities in major markets — including the FDA, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency — are tightening their expectations around data quality, traceability, and consistency well before a drug reaches later-stage testing. For companies with ambitions to launch in multiple countries, that means Phase I can no longer be treated as a narrow safety-and-tolerability exercise. Instead, it becomes the foundation for everything that follows.

Historically, sponsors waited until Phase III — once efficacy data started rolling in — to lock down their global regulatory strategy. AXIS Clinicals notes that this timeline has shifted meaningfully earlier. Regulators increasingly want to see, from the outset, that companies are validating bioanalytical methods, formatting data to CDISC standards, considering population diversity, and watching for early safety signals. Skip that groundwork, the blog warns, and sponsors risk rework, bridging studies, or a barrage of questions when they eventually file IND amendments or marketing applications.

Data Infrastructure Takes Center Stage

Much of the post focuses on the practical machinery behind “submission-ready” data. Phase I trials generate dense pharmacokinetic and safety datasets, and the blog points to several tools sponsors are leaning on to keep that data audit-ready: direct eSource-to-EDC integration to cut down on transcription errors, standardized case report forms built around global regulatory norms, and earlier database-lock preparation to compress timelines further down the pipeline. The message is blunt — regulators don’t just want accurate numbers, they want data that can withstand scrutiny at any point in a study’s lifecycle, a bar the post suggests agencies are raising heading into 2026.

Bioanalytical Planning as an Overlooked Lever

One of the more technical arguments in the piece centers on bioanalytical strategy, an area the blog says sponsors frequently underrate. Regional differences — such as whether a trial relies on whole blood versus plasma or serum, along with varying expectations for assay sensitivity and sample stability — can create real headaches if they aren’t ironed out early. Establishing a bioanalytical approach that holds up across regions, the post argues, means fewer repeat or bridging analyses later, more consistent pharmacokinetic datasets across multiple filings, and a smoother path into later trial phases.

Regional Nuance Still Rules

Despite years of harmonization work under ICH guidelines, the blog is careful to note that meaningful differences between regulatory regions persist. It flags variation in first-in-human dose justification requirements, differing safety margins and stopping criteria, and region-specific expectations around ethnic sensitivity and population stratification. Addressing these details during protocol design, rather than after data collection begins, is framed as a way to avoid costly amendments or extra studies down the line.

Designing With the Finish Line in Mind

The post ultimately frames early-phase readiness as a mindset shift rather than a compliance checklist. It encourages sponsors to structure protocols so the resulting data can be used across multiple regions, to build in flexibility for expansion cohorts or added endpoints, and to keep documentation at a global audit standard from day one. Done well, the blog suggests, this turns Phase I from a standalone milestone into a strategic accelerator for reaching international markets.

The Cost of Waiting

The consequences of skipping this early planning, according to the post, are well established: additional bridging studies, delayed IND or CTA approvals, more regulatory queries during review, and longer timelines to market overall. Sponsors that invest in global readiness from the start, by contrast, are described as better positioned to move through development with fewer disruptions and stronger regulatory footing.

As the blog puts it, the line separating early-phase development from submission strategy is fading fast — and sponsors who plan for global markets starting in Phase I stand to gain real ground on those who wait.